nach oben

Tumor Biology

Erschienen in:

01.04.2014 | Research Article

Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis

verfasst von: Riadh Badraoui, Mariem Boubakri, Maissa Bedbabiss, Hmed Ben-Nasr, Tarek Rebai

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

This study was designed to assess femur angioarchitecture and hematological effects of Walker 256/B cells in a rat model of tumor osteolysis. Tumor osteolysis was induced by in situ inoculation of Walker 256/B malignant cells. Six other rats were sham operated and served as control. Twenty days later, rats were euthanized, and femurs were collected than radiographed. Angioarchitecture [mean lumen diameter (MLD), wall thickness (WTh), Vessel number, volume, and separation (VNb, VV, and VSp respectively)] was studied by histomorphometry at 2 different positions (P1: diaphysis, and P2: metaphysis) of the operated femora. Some hematological parameters were also assessed. Walker 256/B induced marked tumor osteolysis, with cortical perforation and trabecular destruction, associated increase in bone vascularization (increases of VNb and VV and decrease of VSp). Angioarchitecture of W256/B rats was disorganized and showed large MLD and lower WTh. These effects were more prominent in P2. When compared to Sham group, significantly decreases at levels of red blood cell (RBC), hemoglobin (Hb), hematocrit (Ht), and white blood cell (WBC) were observed in W256/B rats. These results suggest that Walker 256/B cells induced tumor osteolysis, improve hypervasculature especially near the tumoral foci (P2) associated hematological disruption. Besides, tumor vessels showed abnormal (enlarged and thinner) and disorganized morphology.

Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI. Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy. J Clin Oncol. 2010;28:4892–7.PubMedCrossRef

Fong JE, Le Nihouannen D, Komarova SV. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of g-secretase. J Biol Chem. 2010;285:31427–34.PubMedCentralPubMedCrossRef

Ara T, DeClerck Y. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46:1223–31.PubMedCentralPubMedCrossRef

Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D, et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related metastases. J Cell Physiol. 2011;226:780–4.

Tiedemann K, Hussein O, Sadvakassova G, Guo Y, Siegel PM, Komarova SV. Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways. J Biol Chem. 2009;284:33662–70.PubMedCentralPubMedCrossRef

Bhat TA, Singh RP. Tumor angiogenesis—a potential target in cancer chemoprevention. Food Chem Toxicol. 2008;46:1334–45.PubMedCrossRef

Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–49.PubMedCrossRef

Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011;48(1):6–15

Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.PubMedCrossRef

10.

Drevs J. VEGF and angiogenesis: implications for breast cancer therapy. Eur J Cancer. 2008;6:7–13.CrossRef

11.

Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, et al. Osteoclasts are important for bone angiogenesis. Blood. 2010;115:140–9.PubMedCrossRef

12.

Collet G, Skrzypek K, Grillon C, Matejuk A, Hafni-Rahbi BE, Lamerant-Fayel N, et al. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vasc Pharmacol. 2012;56:252–61.CrossRef

13.

Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 2007;67:4157–63.PubMedCrossRef

14.

Lynch CC. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone. 2011;48:44–53.PubMedCrossRef

15.

Shojaei F. Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett. 2012;320:130–7.PubMedCrossRef

16.

Heymann D. Anti-RANKL therapy for bone tumours: basic, pre-clinical and clinical evidences. J Bone Oncol. 2012;1:2–11.CrossRef

17.

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.PubMedCrossRef

18.

Mastro AM, Gay CV, Welch DR. The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis. 2003;20:275–84.PubMedCrossRef

19.

Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27:41–55.PubMedCrossRef

20.

Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6:93–106.PubMedCrossRef

21.

Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol. 2012;23:834–43.PubMedCrossRef

22.

Badraoui R, Rebai T. Effect of malignant ascites on antioxidative potency of two tumoral cells-induced bone metastases: Walker 256/B and MatLyLu. Exp Toxicol Pathol. 2012;64:65–8.PubMedCrossRef

23.

Badraoui R, Blouin S, Moreau MF, Gallois Y, Rebai T, Sahnoun Z, et al. Effect of alpha tocopherol acetate in Walker 256/B cells-induced oxidative damage in a rat model of breast cancer skeletal metastases. Chem Biol Interact. 2009;182:98–105.PubMedCrossRef

24.

Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF, et al. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256/B mammary gland carcinoma cells. Biochem Biophys Res Commun. 2006;345:1292–8.PubMedCrossRef

25.

Blouin S, Moreau MF, Baslé MF, Chappard D. Relations between radiograph texture analysis and microcomputed tomography in two rat model of bone metastases. Cells Tissues Organs. 2006;182:182–92.PubMedCrossRef

26.

Chappard D, Bouvard B, Baslé MF, Legrand E, Audran M. Bone metastasis: Histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review. Morphologie. 2011;95:65–75.PubMedCrossRef

27.

Chappard D, Libouban H, Legrand E, Ifrah N, Masson C, Baslé MF, et al. Computed microtomography of bone specimens for rapid analysis of bone changes associated with malignancy. Anat Rec. 2010;293:1125–33.CrossRef

28.

Brandi ML, Collin-Osdoby P. Vascular biology and the skeleton. J Bone Miner Res. 2006;21:183–92.PubMedCrossRef

29.

Portal-Núñez S, Lozano D, Esbrit P. Role of angiogenesis on bone formation. Histol Histopathol. 2012;27:559–66.PubMed

30.

Nyangoga H, Mercier P, Libouban H, Basle MF, Chappard D. Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (MicroCT). PLoS ONE. 2011;6:e17336.PubMedCentralPubMedCrossRef

31.

Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res. 2001;61:2145–53.PubMed

32.

Guise TA, Kozlow WM, Heras-Herig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 2005;5:S46–53.PubMedCrossRef

33.

Ellis SL, Grassinger J, Jones A, Camenisch T, Haylock D, Bertoncello I, et al. The relationship between bone, hemopoietic stem cells, and vasculature. Blood. 2011;118:1516–24.PubMedCrossRef

34.

Jiang Y, Bonig H, Ulyagova T, Chang K, Papayannopoulou T. On the adaptation of endosteal stem cell niche function in response to stress. Blood. 2009;114:3773–82.PubMedCentralPubMedCrossRef

35.

Roux S, Mariette X. Hematological malignancies and the bone (myeloma excluded). Joint Bone Spine. 2000;67:264–71.PubMed

36.

Iriuchishima H, Takubo K, Miyakawa Y, Nakamura-Ishizu A, Miyauchi Y, Fujita N, et al. Neovascular niche for human myeloma cells in immunodeficient mouse bone. PLoS ONE. 2012;7:e30557.PubMedCentralPubMedCrossRef

37.

Caolo V, Molin DGM, Post MJ. Notch Regulation of Hematopoiesis, Endothelial Precursor Cells, and Blood Vessel Formation: Orchestrating the Vasculature. Stem Cells Int. 2012 doi:10.1155/2012/805602.

38.

Kwon JH, Shin JH, Kim JH, Gwon DI, Yoon HK, Ko GY, et al. Preoperative transcatheter arterial embolization of hypervascular metastatic tumors of long bones. Acta Radiol. 2010;51:396–401.PubMedCrossRef

39.

Palli D, Berrino F, Vineis P, Tumino R, Panico S, Masala G, et al. A molecular epidemiology project on diet and cancer: the EPIC-Italy prospective study. Design and baseline characteristics of participants. Tumori. 2003;89:586–93.PubMed

40.

De Vizcaya-Ruiz A, Rivero-Muller A, Ruiz-Ramirez L, Howarth JA, Dobrota M. Hematotoxicity response in rats by the novel copper-based anticancer agent: casiopeina II. Toxicology. 2003;194:103–13.PubMedCrossRef

Titel: Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis
verfasst von: Riadh Badraoui
Mariem Boubakri
Maissa Bedbabiss
Hmed Ben-Nasr
Tarek Rebai
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1485-5

Springer Medizin

Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women

Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients

The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases

The variant interleukin 1f7 rs3811047 G>A was associated with a decreased risk of gastric cardiac adenocarcinoma in a Chinese Han population

N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: evidence from 23 case–control studies

Proto-oncogene Wip1, a member of a new family of proliferative genes in NSCLC and its clinical significance

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie